Nutriband Inc. CEO Temporarily Steps Down to Pursue Irish Presidential Candidacy

Nutriband Inc. (NASDAQ: NTRB) has announced a temporary leadership change as CEO Gareth Sheridan steps aside for three months to pursue his candidacy in the upcoming Irish Presidential election. During this period, Co-Founder and Chairman Serguei Melnik, a seasoned expert in corporate strategy with over two decades of experience in capital markets, will assume the role of CEO. This transition underscores the company's commitment to its strategic goals, including the 2026 NDA filing target for its innovative AVERSA Fentanyl abuse-deterrent opioid patch.

The AVERSA Fentanyl patch represents a significant advancement in the fight against opioid abuse, designed to deter misuse and accidental exposure. With the FDA recently granting a meeting request for this product, Nutriband is poised to make a substantial impact in the pharmaceutical industry. The technology behind AVERSA Fentanyl is protected by patents in 46 countries, highlighting its global potential. Estimates suggest peak U.S. sales could range between $80 million to $200 million, with plans to expand into major global medical markets.

Sheridan expressed confidence in the leadership team's ability to maintain the company's momentum during his temporary absence. The focus remains on advancing AVERSA Fentanyl and other transdermal pharmaceutical products under development. For more details on Nutriband's announcement, visit https://ibn.fm/YstUq.

This leadership transition and the progress on AVERSA Fentanyl underscore Nutriband's strategic positioning in the pharmaceutical industry. The company's innovative approach to abuse-deterrent technology and its global patent portfolio position it for significant growth and impact in addressing the critical issue of opioid abuse.